Gilead’s Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths

In the span of half a year, Gilead’s Trodelvy has flopped a second phase 3 trial.

Following a high-profile setback in non-small cell lung cancer (NSCLC) in January, Gilead said Thursday that Trodelvy also failed to move the needle in a bladder cancer study.